These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 24557872)

  • 1. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
    Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
    Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
    Wolin EM
    Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
    Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus for advanced pancreatic neuroendocrine tumors.
    Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
    N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
    Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
    Flaum N; Valle JW; Mansoor W; McNamara MG
    Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
    Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
    Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J; Tabernero J
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
    QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
    Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
    Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.